Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7486967 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| RO7486967 Arm | EXPERIMENTAL | Participants will receive RO07486967 for approximately 28 days with 14 days of follow up after the last dose. |
| Placebo | PLACEBO_COMPARATOR | Matching placebo |
| Name | Type | Description |
|---|---|---|
| RO7486967 | DRUG | For up to approximately 28 days |
| Placebo | DRUG | For up to approximately 28 days |
Inclusion Key Criteria: * Male or post-menopausal female * Diagnosis of clinically probable idiopathic PD based on MDS criteria with bradykinesia plus one of the other cardinal signs of PD (resting tremor, rigidity) * A time from diagnosis of PD of at least 3 to maximum 60 months (5 years) at scree...
RO7486967 is an investigational small molecule being studied for the treatment of early idiopathic Parkinson's Disease. It is currently in Phase 1 clinical development and is not yet approved by regulatory authorities. The drug is being evaluated for its safety, tolerability, pharmacokinetics, and pharmacodynamics in affected patients.
RO7486967 is being developed by Roche Holding AG, a multinational healthcare company. Roche's stock is traded under the ticker symbol RHHBY on the OTC market. The company is conducting clinical research to evaluate this investigational drug for Parkinson's Disease.
RO7486967 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by the FDA or other regulatory agencies. The Phase 1 trial has been completed, and the drug remains in early-stage clinical research for Parkinson's Disease.
RO7486967 has one completed Phase 1 clinical trial registered under NCT05924243. This study investigated the safety, tolerability, pharmacokinetics, and pharmacodynamics of the drug in 60 participants with early idiopathic Parkinson's Disease. The trial was conducted in the United States, Netherlands, and United Kingdom.
RO7486967 is a small molecule therapeutic being developed for Parkinson's Disease. The specific molecular target and mechanism of action have not been disclosed in available clinical trial information. The drug is being evaluated for its effects on the disease through ongoing clinical research.